secwatch.observer — SEC 8-K summary
======================================

Issuer:     AVENUE THERAPEUTICS, INC. (ATXI)
CIK:        0001644963
Form:       8-K
Filed at:   2023-03-30T23:59:59+00:00
Accession:  0001104659-23-039135
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avenue Therapeutics reports FY2022 net loss of $3.6M; cash $6.7M; pipeline updates
--------------------------------------------------------------------------------

- Net loss $3.6M ($1.63/share) vs $3.7M ($3.29/share) in 2021; R&D $2.7M, G&A $5.3M.
- Cash $6.7M at Dec 31, 2022, up from $3.8M; raised $12M in Oct 2022 offering and $3.25M in Jan 2023.
- In-licensed AJ201 for SBMA (Kennedy's Disease) in Phase 1b/2a; FDA granted Orphan Drug Designation.
- IV Tramadol: Type C meeting with FDA in March 2023; update expected in April 2023.
- Completed acquisition of Baergic Bio in Nov 2022; appointed Alexandra MacLean to board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1644963/000110465923039135/0001104659-23-039135-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1644963/000110465923039135/tm2310303d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-039135

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer